Profitability
Weight: 15%
D-
30
- 5yr Avg ROIC -10.4%
- Operating Margin Trend +194.80 pp/yr
MIRM
Mirum Pharmaceuticals, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -31.4%
- 5yr Share-Count CAGR 13.4%
Growth Quality
Weight: 35%
B-
68
- 5yr Revenue CAGR 128.5%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 4/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -197.0%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
B-
66
- Net Debt / EBITDA -3.71x
- Interest Coverage (EBIT/Int) -0.49x
- Altman Z-Score 3.19
Stability
Weight: 5%
A-
80
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 3
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.4 of 4 gurus held; 2 new buys; 2 trimmed.
- Holders
- 4 +2
- Avg Δ position
- -50.9%
- New buys
- 2
- Full exits
- 0
- Greenblatt new
- Laffont new
- Cooperman decreased -82%